Krystal Biotech Inc
NASDAQ:KRYS
Intrinsic Value
Krystal Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development of redosable gene therapies to improve the lives of patients living with rare diseases. [ Read More ]
The intrinsic value of one KRYS stock under the Base Case scenario is 123.92 USD. Compared to the current market price of 163.97 USD, Krystal Biotech Inc is Overvalued by 24%.
Valuation Backtest
Krystal Biotech Inc
Run backtest to discover the historical profit from buying and selling KRYS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Krystal Biotech Inc
Current Assets | 587.9m |
Cash & Short-Term Investments | 532.2m |
Receivables | 42m |
Other Current Assets | 13.7m |
Non-Current Assets | 230.4m |
Long-Term Investments | 62m |
PP&E | 168.2m |
Other Non-Current Assets | 263k |
Current Liabilities | 33.1m |
Accounts Payable | 4.1m |
Accrued Liabilities | 24.5m |
Other Current Liabilities | 4.5m |
Non-Current Liabilities | 6.6m |
Other Non-Current Liabilities | 6.6m |
Earnings Waterfall
Krystal Biotech Inc
Revenue
|
50.7m
USD
|
Cost of Revenue
|
-3.1m
USD
|
Gross Profit
|
47.6m
USD
|
Operating Expenses
|
-144.8m
USD
|
Operating Income
|
-97.2m
USD
|
Other Expenses
|
108.2m
USD
|
Net Income
|
10.9m
USD
|
Free Cash Flow Analysis
Krystal Biotech Inc
What is Free Cash Flow?
KRYS Profitability Score
Profitability Due Diligence
Krystal Biotech Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
Krystal Biotech Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
KRYS Solvency Score
Solvency Due Diligence
Krystal Biotech Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Krystal Biotech Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
KRYS Price Targets Summary
Krystal Biotech Inc
According to Wall Street analysts, the average 1-year price target for KRYS is 192.27 USD with a low forecast of 154.53 USD and a high forecast of 218.4 USD.
Ownership
KRYS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
KRYS Price
Krystal Biotech Inc
Average Annual Return | 27.96% |
Standard Deviation of Annual Returns | 33.03% |
Max Drawdown | -25% |
Market Capitalization | 4.6B USD |
Shares Outstanding | 28 514 500 |
Percentage of Shares Shorted | 10.08% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Krystal Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development of redosable gene therapies to improve the lives of patients living with rare diseases. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 119 full-time employees. The company went IPO on 2017-09-20. Using its platform that is based on engineered herpes simplex virus type 1 (HSV-1), the Company create vectors that deliver therapeutic transgenes to cells of interest in multiple organ systems. The Company’s gene therapy product candidates and undertaking preclinical studies and clinical trials of B-VEC, KB105, KB301, KB104, KB407 and KB408. The firm's KB104 is to treat Netherton Syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation, itchiness, and dehydration.
Contact
IPO
Employees
Officers
The intrinsic value of one KRYS stock under the Base Case scenario is 123.92 USD.
Compared to the current market price of 163.97 USD, Krystal Biotech Inc is Overvalued by 24%.